542 related articles for article (PubMed ID: 26222558)
21. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene.
Brahmi M; Alberti L; Tirode F; Karanian M; Eberst L; Pissaloux D; Cassier P; Blay JY
Ann Oncol; 2018 Jun; 29(6):1488-1489. PubMed ID: 29668829
[No Abstract] [Full Text] [Related]
22. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
[TBL] [Abstract][Full Text] [Related]
23. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
[TBL] [Abstract][Full Text] [Related]
24. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
Giustini N; Bernthal NM; Bukata SV; Singh AS
Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
[TBL] [Abstract][Full Text] [Related]
25. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.
Sikaria S; Heim-Hall J; Diaz EH; Williams R; Sankhala K; Laabs B; Mita M
Target Oncol; 2014 Mar; 9(1):73-9. PubMed ID: 23430345
[No Abstract] [Full Text] [Related]
26. [Tenosynovial giant cell tumor].
Kuhnen C; Müller KM; Rabstein S; Kasprzynski A; Herter P
Pathologe; 2005 Mar; 26(2):96-110. PubMed ID: 15657685
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue.
Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T
Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082
[TBL] [Abstract][Full Text] [Related]
28. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Smeester BA; Slipek NJ; Pomeroy EJ; Laoharawee K; Osum SH; Larsson AT; Williams KB; Stratton N; Yamamoto K; Peterson JJ; Rathe SK; Mills LJ; Hudson WA; Crosby MR; Wang M; Rahrmann EP; Moriarity BS; Largaespada DA
Bone; 2020 Jul; 136():115353. PubMed ID: 32251854
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
30. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
[TBL] [Abstract][Full Text] [Related]
31. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
[TBL] [Abstract][Full Text] [Related]
32. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
[TBL] [Abstract][Full Text] [Related]
33. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
[TBL] [Abstract][Full Text] [Related]
36. Cytologic findings in tenosynovial giant cell tumors investigated by fine-needle aspiration cytology.
Layfield LJ; Moffatt EJ; Dodd LG; Scully SP; Harrelson JM
Diagn Cytopathol; 1997 Apr; 16(4):317-25. PubMed ID: 9143824
[TBL] [Abstract][Full Text] [Related]
37. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.
Cheng H; Clarkson PW; Gao D; Pacheco M; Wang Y; Nielsen TO
Sarcoma; 2010; 2010():174528. PubMed ID: 20981142
[TBL] [Abstract][Full Text] [Related]
39. The growing problem of benign connective tissue tumours.
Thomas DM
Lancet Oncol; 2015 Aug; 16(8):879-80. PubMed ID: 26179199
[No Abstract] [Full Text] [Related]
40. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Peterfy C; Chen Y; Countryman P; Chmielowski B; Anthony SP; Healey JH; Wainberg ZA; Cohn AL; Shapiro GI; Keedy VL; Singh A; Puzanov I; Wagner AJ; Qian M; Sterba M; Hsu HH; Tong-Starksen S; Tap WD
Future Oncol; 2022 Apr; 18(12):1449-1459. PubMed ID: 35040698
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
